NBI-6024 belongs to a proprietary altered peptide ligand (APL) technology developed by Neurocrine Biosciences for the treatment of autoimmune diseases. It is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production. NBI-6024 corresponds to the 9-23 amino acid region of the insulin B chain (B(9-23)), an epitope recognized by inflammatory interferon-gamma-producing T helper (Th)1 lymphocytes in type 1 diabetic patients. NBI-6024 is designed specifically to generate an immune response that could result in preservation of beta-islet cell function in patients with Type I diabetes or juvenile-onset diabetes. Because there is progressive beta-islet destruction in Type I diabetes, an early intervention strategy with a product like NBI-6024 could delay or prevent insulin dependence.